About us
Founded in 2015 by two scientists, Géraldine Le Duc (CEO of NH TherAguix) and Pr Olivier Tillement (Professor of Chemistry at University of Lyon), NH TherAguix is a French biotechnology company based in Grenoble. NH TherAguix has developed an innovative theranostic nanodrug called AGuIX® that allows to fight more efficiently against all forms of cancer.
Thanks to a €13M fund raising in 2019 (BPI, Innobio, Omnes, Arbevel, Supernova), NH THerAguix was able to launch a promising portfolio of clinical trials.
Management

Géraldine Le Duc, PhD
Chief Executive Officer & Co-Founder
- 30 years of expertise in drugs for radiotherapy and imaging of cancer (Guerbet, INSERM, BNL-USA, ESRF)
- More than 100 scientific publications, 4 patents
- Discovery of the radiosensitization effect of AGuIX®
- PhD in Biomedical Physics

Markus Loeffler, MD & MBA
Chief Medical Officer
- More than 20 years of international leadership experience in oncology (Boehringer Ingelheim, Roche, AAA, Mundipharma EDO)
- Expertise in all stages of research and clinical development from first in human to market
- MD & MBA from INSEAD

Michel Julien, PhD
CMC Director
- Over 20 years of experience in parenteral drug research and development
- Strong expertise in CMC activities from lead candidate selection to manufacturing process validation including management of CMOs
- PhD in Biochemistry

Caroline Cayre
Head of Finance and Administration
- 25+ years spent in Finance & Business administration, including 15 years in international business environment
- Broad industry experience: Audit (PwC), Large international groups (HP), Fast growing SMEs/Start-ups (Aledia)
- French Business School (1995) – Studies abroad (Bath-UK), Certified Coach (Teams & Organizations)
Board of directors

Géraldine Le Duc
CEO & Co-Founder

Hervé Brailly
Chairman

Philippe Boucheron
Life Sciences Investor
Bpifrance

Thibaut Roulon
Life Sciences Investor
Bpifrance

Nitza Thomasson
Life Sciences Investor
Omnes

Marc Lebozec
Life Sciences Investor
Arbevel

Célia Hart
Life Sciences Investor
Supernova

Yannick Pletan
Formely Country Medical Director
Roche

Philippe Archinard
Deputy CEO-Innovation & Scientific Partnerships
Institut Mérieux
Partners






